Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients.

摘要: Background: Despite improvement of tumor response rates, targeted therapy may induce toxicities in cancer patients. Recent studies indicate amelioration adverse events (AEs) by add-on mistletoe (Viscum album L., VA) standard oncological treatment. The primary objective this multicenter observational study was to determine the safety profile and VA compared alone. Methods: Demographic medical data were retrieved from Network Oncology registry. Allocation either control (targeted therapy) or combinational group (targeted/add-on performed. Safety-associated variables evaluated adjusted multivariable analyses. Results: median age population (n = 310) at first diagnosis 59 years; 67.4% female. In total, 126 patients (40.6%) 184 (59.4%) combination group. Significant differences observed between both groups with respect overall AE frequency (χ² 4.1, p 0.04) discontinuation treatment 4.8, 0.03) lower rates (20.1%, 35% respectively) (30.2%, 60.5%, respectively). Addition significantly reduced probability 70% (Odds ratio (OR) 0.30, 0.02). Conclusions: Our results a highly significant reduction AE-induced all-stage when treated addition therapy.